A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00883779 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

451

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Placebo
DRUG: Platinum chemotherapy (cisplatin or carboplatin)
DRUG: erlotinib [Tarceva]
DRUG: gemcitabine

Sponsor

Hoffmann-La Roche